SCHEMBL5136052

SCHEMBL5136052

CCCCn1c(CN(Cc2ccccc2)Cc2ccc(C)c(C)c2)cnc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
HSD11B1 P28845 2/20 0.40
C5AR1 P21730 1/20 0.40
PDE4B Q07343 2/20 0.35
NR1H3 Q13133 1/20 0.34
BCHE P06276 1/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
ADORA2B P29275 1/20 0.34
CNR2 P34972 2/20 0.33
BRD4 O60885 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CNR1 P21554 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135793 0.93 TSHR (0.37) TSHRHSD11B1C5AR1KDM4EHSD17B10
SCHEMBL5135358 0.92 HSD11B1 (0.42) TSHRHSD11B1C5AR1BCHE
SCHEMBL5072278 0.91 TSHR (0.51) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5134992 0.91 TSHR (0.41) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5136591 0.91 TSHR (0.41) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5136164 0.91 TSHR (0.41) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5135386 0.91 TSHR (0.41) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5136484 0.89 TSHR (0.45) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5137319 0.89 TSHR (0.47) TSHRHSD11B1C5AR1PDE4BNR1H3
SCHEMBL5070162 0.89 TSHR (0.47) TSHRHSD11B1C5AR1PDE4BNR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed